Your browser is no longer supported. Please, upgrade your browser.
Settings
ARWR Arrowhead Pharmaceuticals, Inc. daily Stock Chart
ARWR [NASD]
Arrowhead Pharmaceuticals, Inc.
Index- P/E376.85 EPS (ttm)0.07 Insider Own4.20% Shs Outstand95.95M Perf Week4.32%
Market Cap2.64B Forward P/E- EPS next Y-0.27 Insider Trans-22.50% Shs Float86.49M Perf Month45.25%
Income9.60M PEG51.41 EPS next Q0.26 Inst Own63.50% Short Float22.14% Perf Quarter48.38%
Sales94.80M P/S27.84 EPS this Y-39.90% Inst Trans0.55% Short Ratio9.47 Perf Half Y97.06%
Book/sh2.14 P/B12.86 EPS next Y-139.70% ROA4.30% Target Price28.08 Perf Year100.36%
Cash/sh2.27 P/C12.10 EPS next 5Y7.33% ROE6.70% 52W Range10.41 - 28.19 Perf YTD121.50%
Dividend- P/FCF20.35 EPS past 5Y12.90% ROI-57.00% 52W High-2.27% Beta1.63
Dividend %- Quick Ratio2.30 Sales past 5Y123.40% Gross Margin- 52W Low164.65% ATR1.13
Employees116 Current Ratio2.30 Sales Q/Q7306.00% Oper. Margin6.20% RSI (14)69.02 Volatility3.10% 4.75%
OptionableYes Debt/Eq0.00 EPS Q/Q237.60% Profit Margin10.10% Rel Volume0.61 Prev Close27.51
ShortableYes LT Debt/Eq0.00 EarningsMay 08 AMC Payout0.00% Avg Volume2.02M Price27.55
Recom1.80 SMA208.07% SMA5028.31% SMA20060.92% Volume291,213 Change0.15%
Sep-07-18Upgrade B. Riley FBR Neutral → Buy $18 → $19
Sep-06-18Reiterated Chardan Capital Markets Buy $17.50 → $24.50
Aug-08-18Reiterated Cantor Fitzgerald Overweight $13 → $18
Jul-02-18Reiterated Chardan Capital Markets Buy $9.50 → $16
May-09-18Upgrade Cantor Fitzgerald Neutral → Overweight $13
Mar-27-18Initiated Jefferies Buy $10
Feb-12-18Reiterated Cantor Fitzgerald Neutral $2 → $5
Feb-12-18Reiterated B. Riley FBR, Inc. Neutral $3 → $4
Jan-05-18Initiated B. Riley FBR, Inc. Neutral $3
Nov-27-17Upgrade Piper Jaffray Neutral → Overweight
Sep-18-17Upgrade William Blair Mkt Perform → Outperform
Nov-30-16Downgrade William Blair Outperform → Mkt Perform
Nov-30-16Downgrade Piper Jaffray Overweight → Neutral
Nov-30-16Downgrade Chardan Capital Markets Buy → Neutral $8 → $2
Nov-30-16Downgrade Cantor Fitzgerald Buy → Hold
Nov-10-16Reiterated Chardan Capital Markets Buy $10 → $8
Aug-18-16Initiated Cantor Fitzgerald Buy $15
May-19-16Initiated Chardan Capital Markets Buy $12
Sep-25-15Reiterated Piper Jaffray Overweight $12 → $20
Oct-09-14Downgrade RBC Capital Mkts Outperform → Sector Perform $35 → $9
Jun-14-19 02:59PM  7 Top-Rated Biotech Stocks to Invest In Today InvestorPlace
Jun-12-19 03:32PM  Edited Transcript of ARWR earnings conference call or presentation 12-Dec-17 9:30pm GMT Thomson Reuters StreetEvents
Jun-11-19 03:44PM  Edited Transcript of ARWR earnings conference call or presentation 8-May-19 8:30pm GMT Thomson Reuters StreetEvents
Jun-10-19 10:02AM  Read This Before Judging Arrowhead Pharmaceuticals, Inc.'s (NASDAQ:ARWR) ROE Simply Wall St.
06:30AM  Here's Why Arrowhead Pharmaceuticals Surged 31.9% in May Motley Fool
May-31-19 04:00PM  Arrowhead Pharmaceuticals to Present at Upcoming June 2019 Conferences Business Wire
May-21-19 04:27PM  Here's Why Arrowhead Pharmaceuticals Skyrocketed 12.7% Today Motley Fool +12.72%
07:40AM  The Daily Biotech Pulse: Setback For Merck In Breast Cancer Study, Arrowhead to Join S&P SmallCap 600 Index, Ocular's Glaucoma Trial Fails Benzinga
May-20-19 05:56PM  Kontoor Brands and Arrowhead Pharmaceuticals Set to Join S&P SmallCap 600 PR Newswire
03:45PM  ARWR: ARO-AAT Ph 2/3 Detailed, Could Serve as FDA Pivotal Study. Continued Broad-Based Pipeline Progress Zacks Small Cap Research
May-09-19 01:23AM  Arrowhead Research Corp (ARWR) Q2 2019 Earnings Call Transcript Motley Fool +6.11%
May-08-19 04:06PM  Arrowhead Research: Fiscal 2Q Earnings Snapshot Associated Press
04:00PM  Arrowhead Pharmaceuticals Reports Fiscal 2019 Second Quarter Results Business Wire
02:30PM  Arrowhead Pharmaceuticals, Inc. to Host Earnings Call ACCESSWIRE
May-02-19 04:05PM  Heres What Hedge Funds Think About Arrowhead Pharmaceuticals, Inc. (ARWR) Insider Monkey
07:30AM  Arrowhead Pharmaceuticals to Present at Upcoming May 2019 Conferences Business Wire
May-01-19 07:06PM  Cramer's lighting round: The quarter won't be good, but buy this stock CNBC
Apr-25-19 03:01PM  Did You Miss Arrowhead Pharmaceuticals's (NASDAQ:ARWR) Impressive 217% Share Price Gain? Simply Wall St.
Apr-24-19 04:00PM  Arrowhead Pharmaceuticals to Webcast Fiscal 2019 Second Quarter Results Business Wire
07:30AM  Arrowhead Begins Triple Combination Cohort in Chronic HBV Patients and Earns $25 Million Milestone Payment from Janssen Business Wire
Apr-21-19 07:57AM  Revamp at Silence does little to improve investors wellbeing Financial Times
Apr-15-19 07:30AM  Arrowhead Pharmaceuticals Receives FDA Clearance to Begin Phase 2/3 Study of ARO-AAT for Treatment of Alpha-1 Liver Disease Business Wire
Apr-12-19 12:45PM  Arrowhead Presents Clinical Data on JNJ-3989 (ARO-HBV) at The International Liver Congress Business Wire
06:00AM  Arrowhead Preclinical Data Demonstrates RNAi Therapy Prevents and Reverses Alpha-1 Liver Disease at The International Liver Congress Business Wire
Apr-11-19 09:27AM  4 Drug/Biotech Stocks Making a Mark in RNAi Therapeutics Zacks
Mar-29-19 04:30PM  Arrowhead Pharmaceuticals Reports Inducement Grants under NASDAQ Marketplace Rule 5635(c)(4) Business Wire
Mar-27-19 07:35AM  Research Report Identifies Criteo S.A, Ferrari N.V, Freshpet, ServiceMaster Global, CSG Systems International, and Arrowhead Pharmaceuticals with Renewed Outlook Fundamental Analysis, Calculating Forward Movement GlobeNewswire
Mar-22-19 04:16PM  Produce with the most pesticides in your grocery store Yahoo Finance -6.82%
Mar-18-19 07:30AM  Arrowhead Pharmaceuticals Files IND for Pivotal Phase 2/3 Study of ARO-AAT for Treatment of Alpha-1 Liver Disease Business Wire
Mar-11-19 07:30AM  Arrowhead Pharmaceuticals Begins Dosing in Phase 1 Study of ARO-APOC3 for Treatment of Hypertriglyceridemia Business Wire
02:25AM  Here's Why Arrowhead Pharmaceuticals Gained 38.2% in February Motley Fool
Mar-07-19 08:01AM  Does Arrowhead Pharmaceuticals, Inc.s (NASDAQ:ARWR) CEO Salary Reflect Performance? Simply Wall St.
Mar-01-19 07:30AM  Arrowhead Pharmaceuticals to Present at Upcoming March 2019 Conferences Business Wire
Feb-12-19 12:00PM  ARWRs 2019 Goals Include Data From Several Studies, Initiation of Ph2 ARO-AAT Zacks Small Cap Research
11:14AM  Edited Transcript of ARWR earnings conference call or presentation 7-Feb-19 9:30pm GMT Thomson Reuters StreetEvents
08:30AM  Biotech Stocks Rising ACCESSWIRE
Feb-08-19 12:20PM  Here's Why Arrowhead Pharmaceuticals Gained as Much as 15.8% Today Motley Fool +17.74%
Feb-07-19 11:24PM  Arrowhead Pharmaceuticals Inc (ARWR) Q1 2019 Earnings Conference Call Transcript Motley Fool
05:25PM  Arrowhead Research: Fiscal 1Q Earnings Snapshot Associated Press
04:00PM  Arrowhead Pharmaceuticals Reports Fiscal 2019 First Quarter Results Business Wire
08:08AM  The Daily Biotech Pulse: Galapagos-Evotec Forge Fibrosis Partnership, Sanofi Earnings, Alector To Debut Benzinga
Jan-31-19 07:35AM  Report: Exploring Fundamental Drivers Behind TD Ameritrade Holding, Vertex Pharmaceuticals, Arrowhead Pharmaceuticals, Nucor, Portland General Electric, and TrueBlue New Horizons, Emerging Trends, and Upcoming Developments GlobeNewswire
Jan-30-19 07:00AM  Have Insiders Been Selling Arrowhead Pharmaceuticals, Inc. (NASDAQ:ARWR) Shares? Simply Wall St.
Jan-24-19 04:00PM  Arrowhead Pharmaceuticals to Webcast Fiscal 2019 First Quarter Results Business Wire
Jan-22-19 02:48PM  5 Hot Small-Cap Stocks That Are a Bit Too Toasty InvestorPlace -9.78%
Jan-12-19 09:07AM  Here's Why Arrowhead Pharmaceuticals Shot 237.5% Higher in 2018 Motley Fool
Jan-07-19 07:30AM  Arrowhead Pharmaceuticals Files for Regulatory Clearance to Begin Phase 1 Study of ARO-APOC3 for Treatment of Hypertriglyceridemia Business Wire +7.06%
07:30AM  Arrowhead Pharmaceuticals Begins Dosing in Phase 1 Study of ARO-ANG3 for Treatment of Dyslipidemias and Metabolic Diseases Business Wire
Jan-06-19 09:16PM  Edited Transcript of ARWR earnings conference call or presentation 11-Dec-18 9:30pm GMT Thomson Reuters StreetEvents
Dec-21-18 11:19PM  Arrowhead Research Corp (ARWR): Hedge Funds Are Snapping Up Insider Monkey -12.90%
Dec-17-18 06:06PM  Arrowhead Pharmaceuticals Reports Inducement Grants under NASDAQ Marketplace Rule 5635(c)(4) Business Wire
Dec-12-18 04:51PM  Why Arrowhead Pharmaceuticals Surged 11% Higher Today Motley Fool +11.53%
08:07AM  The Daily Biotech Pulse: Legal Victory For Boston Scientific, Alder Gets New CFO, FDA Go-Ahead For BioXcel Benzinga
07:00AM  Today's Research Reports on Trending Tickers: Arrowhead Pharmaceuticals and Agios Pharmaceuticals ACCESSWIRE
12:13AM  Arrowhead Pharmaceuticals (ARWR) Q4 2018 Earnings Conference Call Transcript Motley Fool
Dec-11-18 04:00PM  Arrowhead Pharmaceuticals Reports Fiscal 2018 Year End Results Business Wire
08:22AM  The Daily Biotech Pulse: Management Change At Merck, Jazz Buyback, Arrowhead Earnings Benzinga
Dec-10-18 06:18PM  Here's Why Arrowhead Pharmaceuticals Jumped 14.1% in November Motley Fool
Dec-04-18 04:58PM  J&J Strikes Deal with argenx to Co-Develop Cancer Antibody Zacks -10.34%
Nov-30-18 07:25AM  Detailed Research: Economic Perspectives on Arrowhead Pharmaceuticals, NexGen Energy, ArcBest, Cigna, The Allstate, and Comtech Telecommunications What Drives Growth in Today's Competitive Landscape GlobeNewswire
Nov-27-18 07:30AM  Arrowhead Pharmaceuticals to Webcast 2018 Fiscal Year End Results Business Wire
Nov-09-18 12:00PM  Arrowhead Pharmaceuticals Presents Late-Breaking Preliminary Clinical Data on ARO-HBV at Liver Meeting® 2018 Business Wire -5.60%
12:00PM  Arrowhead Pharmaceuticals Presents Late-Breaking Clinical Data on ARO-AAT at Liver Meeting® 2018 Business Wire
Nov-07-18 11:23AM  Here's Why Arrowhead Pharmaceuticals Dropped 33.6% in October Motley Fool +8.25%
Nov-01-18 07:30AM  Arrowhead Pharmaceuticals to Present at Upcoming November 2018 Conferences Business Wire +11.79%
Oct-31-18 07:30AM  Arrowhead Pharmaceuticals Announces Closing of Agreements with Janssen Business Wire
Oct-23-18 08:21AM  Why Investors Are Paying a Premium for These 3 Biotech Stocks Motley Fool
07:25AM  Market Trends Toward New Normal in IAC/InterActiveCorp, Eagle Pharmaceuticals, Arrowhead Pharmaceuticals, The Manitowoc, Brookdale Senior Living, and LATAM Airlines Group S.A Emerging Consolidated Expectations, Analyst Ratings GlobeNewswire
Oct-19-18 11:02AM  The Rally in Arrowhead Pharmaceuticals Has Been Impressive - Now What? TheStreet.com
Oct-16-18 12:01PM  Arrowhead Pharmaceuticals Hosts R&D Day on Pipeline of RNAi Therapeutics Business Wire +5.48%
06:14AM  Johnson & Johnson tops third-quarter earnings, revenue estimates CNBC
Oct-15-18 07:30AM  Arrowhead Pharmaceuticals Files for Regulatory Clearance to Begin Phase 1 Study of ARO-ANG3 Business Wire
Oct-12-18 02:31PM  This 1 Stock Could Send the Entire Healthcare Sector Soaring -- or Plunging Motley Fool
Oct-11-18 03:58PM  Here's Why Arrowhead Pharmaceuticals Skyrocketed Almost 30% in September Motley Fool
12:05PM  Arrowhead to Present Late-Breaking Clinical Data on ARO-AAT and ARO-HBV at AASLD Liver Meeting® 2018 Business Wire
Oct-10-18 10:30AM  Major Biotech Announcements Moving the Market ACCESSWIRE -8.14%
Oct-09-18 10:45AM  ARWR Stock Sinks After Signing a Big Collaboration Deal InvestorPlace
Oct-08-18 08:01AM  Is Arrowhead Pharmaceuticals, Inc. a Buy on the Dip? Motley Fool -6.72%
Oct-05-18 11:30AM  J&J Inks Deal With Arrowhead for Promising Liver Candidate Zacks
09:57AM  Pharma Stock Roundup: PFE to Get New CEO, LLY Presents Impressive Diabetes Data Zacks
08:00AM  Today's Research Reports on Trending Tickers: Arrowhead Pharmaceuticals and Amarin ACCESSWIRE
Oct-04-18 02:49PM  J&J, Arrowhead in gene-silencing drug deal worth up to $3.7 billion Reuters -17.40%
12:17PM  [$$] Honey, I Shrunk the Biotech Deal The Wall Street Journal
11:30AM  Stocks - Apple, Amazon Fall in Pre-market; Barnes & Noble Surges Investing.com
10:12AM  Arrowhead Announces $3.7B License Agreement With Janssen For Gene-Silencing Drug Benzinga
09:19AM  J&J, Arrowhead in gene-silencing drug deal worth up to $3.7 billion Reuters
07:52AM  UPDATE: Arrowhead Pharma stock surges 19% on news of $3.7 billion license agreement with Janssen MarketWatch
07:30AM  Arrowhead Enters $3.7 Billion License and Collaboration Agreements with Janssen Business Wire
Sep-25-18 07:30AM  Arrowhead Pharmaceuticals to Present at Upcoming October 2018 Conferences Business Wire
Sep-24-18 07:30AM  Arrowhead Pharmaceuticals to Host R&D Day on Emerging Pipeline of RNAi Therapeutics Business Wire +5.23%
Sep-21-18 04:00PM  Arrowhead Pharmaceuticals Reports Inducement Grants under NASDAQ Marketplace Rule 5635(c)(4) Business Wire -5.88%
Sep-17-18 08:00AM  Today's Research Reports on Trending Tickers: Geron and Arrowhead Pharmaceuticals ACCESSWIRE
Sep-08-18 07:16AM  3 Biotech Stocks That Soared This Week: Are They Buys? Motley Fool
Sep-07-18 02:10PM  Arrowhead Stock Is Not Done Rallying After Its 38% Jump InvestorPlace
08:00AM  Todays Research Reports on Stocks to Watch: Arrowhead Pharmaceuticals and Iovance Biotherapeutics ACCESSWIRE
07:55AM  The Daily Biotech Pulse: Amgen-AstraZeneca, Boston Scientific Opens Wallet, Advaxis Offering Benzinga
Sep-06-18 04:31PM  Why Cloudera, Arrowhead Pharmaceuticals, and MongoDB Jumped Today Motley Fool +37.52%
01:00PM  This Biotech Broke Out Bullishly On Its Experimental Hepatitis B Drug Investor's Business Daily
12:57PM  Here's What's Behind Arrowhead Pharmaceuticals' Soaring 41.8% Today Motley Fool
10:45AM  Healthcare Stocks Take Center Stage In September ACCESSWIRE
Arrowhead Pharmaceuticals, Inc. develops medicines for the treatment of intractable diseases in the United States. The company's pipeline include ARO-AAT, a RNA interference (RNAi) therapeutic candidate for the treatment of liver diseases associated with alpha-1 antitrypsin deficiency; ARO-APOC3 to treat hypertriglyceridemia; ARO-ANG3 to reduce production of angiopoietin-like protein 3; ARO-ENaC to reduce production of the epithelial sodium channel alpha subunit in the airways of the lung; and ARO-HIF2 for the treatment of clear cell renal cell carcinoma. It is also involved in the development of ARO-HBV, a third-generation subcutaneously administered RNAi therapeutic candidate to treat chronic hepatitis B virus infection; AMG 890 to reduce production of apolipoprotein A; and ARO-AMG1 for treating undisclosed genetically-validated cardiovascular target. Arrowhead Pharmaceuticals, Inc. has collaboration and license agreement with Amgen, Inc.; and Janssen Pharmaceuticals, Inc. to develop RNAi therapeutics. The company was formerly known as Arrowhead Research Corporation and changed its name to Arrowhead Pharmaceuticals, Inc. in April 2016. Arrowhead Pharmaceuticals, Inc. was incorporated in 1989 and is headquartered in Pasadena, California.
Insider Trading Relationship Date Transaction Cost #Shares Value ($) #Shares Total SEC Form 4
Myszkowski Kenneth AllenChief Financial OfficerMay 31Option Exercise4.9435,000172,800313,536Jun 03 06:12 PM
O'Brien PatrickGeneral CounselMay 28Sale24.8830,000746,400203,000May 29 07:01 PM
Anzalone Christopher RichardChief Executive OfficerMay 24Option Exercise2.1349,448105,1102,141,903May 29 06:57 PM
Myszkowski Kenneth AllenChief Financial OfficerMay 21Sale22.0027,071595,562278,536May 22 05:44 PM
Anzalone Christopher RichardChief Executive OfficerApr 03Sale19.3050,000965,0002,092,455Apr 05 06:57 PM
GIVEN BRUCE DChief Operating OfficerMar 01Option Exercise2.0142,50085,425687,106Mar 01 08:42 PM
GIVEN BRUCE DChief Operating OfficerMar 01Sale19.9942,500849,575644,606Mar 01 08:42 PM
GIVEN DOUGLAS BDirectorFeb 26Option Exercise3.9265,000254,570240,130Feb 26 07:32 PM
GIVEN DOUGLAS BDirectorFeb 26Sale19.2565,0001,251,250175,130Feb 26 07:32 PM
GIVEN BRUCE DChief Operating OfficerFeb 25Option Exercise2.0142,50085,425687,106Feb 27 07:08 PM
GIVEN BRUCE DChief Operating OfficerFeb 25Sale18.9842,500806,650644,606Feb 27 07:08 PM
GIVEN DOUGLAS BDirectorFeb 22Sale18.053,00054,150175,130Feb 26 07:32 PM
GIVEN BRUCE DChief Operating OfficerFeb 19Option Exercise2.0142,50085,425687,106Feb 20 08:09 PM
Myszkowski Kenneth AllenChief Financial OfficerFeb 19Option Exercise5.208,00041,600313,607Feb 20 08:12 PM
Myszkowski Kenneth AllenChief Financial OfficerFeb 19Sale18.008,000144,000305,607Feb 20 08:12 PM
GIVEN BRUCE DChief Operating OfficerFeb 19Sale17.9842,500764,150644,606Feb 20 08:09 PM
GIVEN BRUCE DChief Operating OfficerFeb 15Sale17.6726,250463,838644,606Feb 20 08:09 PM
GIVEN BRUCE DChief Operating OfficerFeb 12Option Exercise2.0142,50085,425713,356Feb 12 08:58 PM
GIVEN BRUCE DChief Operating OfficerFeb 12Sale17.0642,500725,050670,856Feb 12 08:58 PM
GIVEN BRUCE DChief Operating OfficerFeb 11Option Exercise2.6211,66730,568825,023Feb 12 08:58 PM
GIVEN BRUCE DChief Operating OfficerFeb 11Sale15.96154,1672,460,995670,856Feb 12 08:58 PM
GIVEN BRUCE DChief Operating OfficerFeb 08Option Exercise2.6211,66730,568859,523Feb 12 08:58 PM
GIVEN BRUCE DChief Operating OfficerFeb 08Sale15.3446,167708,202813,356Feb 12 08:58 PM
GIVEN BRUCE DChief Operating OfficerFeb 05Sale14.4822,500325,800847,856Feb 07 08:35 PM
GIVEN BRUCE DChief Operating OfficerFeb 01Sale13.8528,500394,725870,356Feb 01 07:51 PM
GIVEN BRUCE DChief Operating OfficerJan 23Sale13.1517,500230,125898,856Jan 24 08:53 PM
GIVEN BRUCE DChief Operating OfficerJan 22Sale13.59152,0002,065,680916,356Jan 24 08:53 PM
GIVEN DOUGLAS BDirectorJan 22Sale13.583,00040,740178,130Jan 24 08:46 PM
O'Brien PatrickGeneral CounselJan 18Sale14.4372,0001,038,960233,000Jan 18 07:02 PM
Myszkowski Kenneth AllenChief Financial OfficerJan 17Sale14.5581,8751,191,281305,607Jan 18 07:00 PM
GIVEN BRUCE DChief Operating OfficerJan 14Option Exercise2.9012,66636,7651,111,022Jan 16 08:18 PM
Li ZhenSnr. VP, Chem and Non-Clin DevJan 14Sale14.3440,500580,770201,700Jan 16 08:24 PM
GIVEN BRUCE DChief Operating OfficerJan 14Sale14.4042,666614,3901,068,356Jan 16 08:18 PM
Waddill William D.DirectorJan 11Sale14.778,500125,54546,500Jan 11 06:15 PM
Myszkowski Kenneth AllenChief Financial OfficerJan 02Sale11.988,33399,829387,482Jan 03 07:55 PM
GIVEN BRUCE DChief Operating OfficerJan 02Sale11.9820,000239,6001,098,356Jan 03 07:53 PM
GIVEN DOUGLAS BDirectorDec 27Sale12.003,00036,000145,130Dec 28 05:20 PM
Anzalone Christopher RichardChief Executive OfficerDec 19Sale13.9290,0001,252,8001,542,455Dec 21 05:15 PM
Anzalone Christopher RichardChief Executive OfficerDec 12Sale14.0790,0001,266,3001,632,455Dec 14 05:18 PM
GIVEN DOUGLAS BDirectorNov 23Sale12.743,00038,220148,130Nov 26 09:09 PM
Anzalone Christopher RichardChief Executive OfficerNov 09Sale14.3981,5001,172,7051,722,455Nov 09 07:01 PM
Leone Peter BrianVP, Strategic Bus. InitiativesOct 19Option Exercise6.20131,137812,512261,137Oct 23 07:59 PM
Leone Peter BrianVP, Strategic Bus. InitiativesOct 19Sale13.49131,1371,769,038130,000Oct 23 07:59 PM
Myszkowski Kenneth AllenChief Financial OfficerSep 06Option Exercise3.5745,000160,500355,815Sep 10 06:32 PM
Myszkowski Kenneth AllenChief Financial OfficerSep 06Sale19.3445,000870,200310,815Sep 10 06:32 PM
Anzalone Christopher RichardChief Executive OfficerSep 04Sale14.4564,834936,8511,803,955Sep 05 04:23 PM
Anzalone Christopher RichardChief Executive OfficerAug 31Sale14.45100,0001,445,0001,868,789Sep 05 04:23 PM